Scholarlink

<p>Diabetic retinopathy (DR), a leading cause of blindness, is driven by pathological angiogenesis and vascular leakage, but the underlying epigenetic mechanisms remain poorly defined. Here, we identify the histone demethylase KDM6A as a critical epigenetic regulator promoting DR pathogenesis via Müller cells. KDM6A expression is significantly elevated in human DR retinas and diabetic mouse models. Intravitreal silencing of <i>Kdm6a</i> ameliorates retinal vascular dysfunction, reducing neovascularization, leakage, and acellular capillaries while restoring endothelial tight junctions. Single-cell RNA sequencing revealed that <i>Kdm6a</i> knockdown specifically suppresses VEGF signaling and attenuates ferroptosis. Müller cell-specific <i>Kdm6a</i> overexpression exacerbated DR vascular pathology, while in vitro co-cultures confirmed that KDM6A in Müller cells induces endothelial dysfunction. Mechanistically, KDM6A demethylates H3K27me3 at the promoters of pro-ferroptotic genes (e.g., <i>Tfr1</i>, <i>Cybb</i>, <i>Atg7</i>), thereby promoting ferroptosis in Müller cells under high glucose conditions. Crucially, pharmacological or genetic inhibition of KDM6A mitigated high glucose-induced ferroptosis. Our findings establish KDM6A-mediated epigenetic control of Müller cell ferroptosis as a fundamental regulator of diabetic retinal vasculopathy and nominate KDM6A as a promising therapeutic target for DR.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

KDM6A promotes diabetic retinopathy via H3K27me3-dependent ferroptosis in Müller cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Yanjun Wen,
  • Siyue Luo,
  • Cheng Hu,
  • Yikang Ji,
  • Yulin Zhang,
  • Xu Wang,
  • Xin Huang,
  • Yan Wei

摘要

Diabetic retinopathy (DR), a leading cause of blindness, is driven by pathological angiogenesis and vascular leakage, but the underlying epigenetic mechanisms remain poorly defined. Here, we identify the histone demethylase KDM6A as a critical epigenetic regulator promoting DR pathogenesis via Müller cells. KDM6A expression is significantly elevated in human DR retinas and diabetic mouse models. Intravitreal silencing of Kdm6a ameliorates retinal vascular dysfunction, reducing neovascularization, leakage, and acellular capillaries while restoring endothelial tight junctions. Single-cell RNA sequencing revealed that Kdm6a knockdown specifically suppresses VEGF signaling and attenuates ferroptosis. Müller cell-specific Kdm6a overexpression exacerbated DR vascular pathology, while in vitro co-cultures confirmed that KDM6A in Müller cells induces endothelial dysfunction. Mechanistically, KDM6A demethylates H3K27me3 at the promoters of pro-ferroptotic genes (e.g., Tfr1, Cybb, Atg7), thereby promoting ferroptosis in Müller cells under high glucose conditions. Crucially, pharmacological or genetic inhibition of KDM6A mitigated high glucose-induced ferroptosis. Our findings establish KDM6A-mediated epigenetic control of Müller cell ferroptosis as a fundamental regulator of diabetic retinal vasculopathy and nominate KDM6A as a promising therapeutic target for DR.